Praxis Precision Medicine... (PRAX)
NASDAQ: PRAX
· Real-Time Price · USD
38.16
0.52 (1.38%)
At close: May 01, 2025, 3:59 PM
39.20
2.73%
Pre-market: May 02, 2025, 04:54 AM EDT
1.38% (1D)
| Bid | 34.02 |
| Market Cap | 769.43M |
| Revenue (ttm) | 8.55M |
| Net Income (ttm) | -182.82M |
| EPS (ttm) | -10.21 |
| PE Ratio (ttm) | -3.74 |
| Forward PE | -3.17 |
| Analyst | Buy |
| Ask | 39.45 |
| Volume | 215,897 |
| Avg. Volume (20D) | 553,698 |
| Open | 37.44 |
| Previous Close | 37.64 |
| Day's Range | 36.61 - 39.21 |
| 52-Week Range | 26.70 - 91.83 |
| Beta | 2.68 |
About PRAX
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression; and PRAX-944, a selective small molecule inhib...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 16, 2020
Employees 116
Stock Exchange NASDAQ
Ticker Symbol PRAX
Website https://www.praxismedicines.com
Analyst Forecast
According to 9 analyst ratings, the average rating for PRAX stock is "Buy." The 12-month stock price forecast is $105, which is an increase of 175.16% from the latest price.
Stock ForecastsNext Earnings Release
Praxis Precision Medicines Inc. is scheduled to release its earnings on May 16, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
-13.08%
Praxis Precision Mediciines shares are trading low...
Unlock content with
Pro Subscription
2 months ago
-40.64%
Praxis Precision Medicines shares are trading lower after the company reported a Q4 EPS miss.
